Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Webcast Interview with CEO

19 Jul 2010 07:00

RNS Number : 5036P
ABCAM Plc
19 July 2010
 



For immediate release

19 July 2010

 

 

RNS REACH

 

ABCAM PLC

("Abcam" or "the Company")

 

Webcast interview with Jonathan Milner, CEO

 

Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is pleased to announce that a webcast interview with Jonathan Milner, the Company's Chief Executive Officer, is ready to view at the London Stock Exchange website:

 

www.londonstockexchange.com/growing-company-interviews

 

In the interview, Dr Milner discusses the dynamics of the antibody marketplace and gives an insight into Abcam's history and operations, highlighting the importance of the internet to the Company's business model.

 

The interview marks the beginning of a series of webcasts hosted by the London Stock Exchange entitled Growing Company Interviews. The interviews are designed to give investors a better understanding of selected companies quoted on the London market.

 

 

For further information please contact:

 

Abcam + 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

 

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic

 

 

 

Notes for editors

 

About Abcam plc

 

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 30 June 2010 it contained 63,000 products, most of which are antibodies, from over 250 suppliers. Abcam employs 270 staff in its four operating companies.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAZQLFFBDFEBBV
Date   Source Headline
2nd Mar 201812:43 pmRNSTotal Voting Rights
19th Feb 20188:44 amRNSBlock listing Interim Review
2nd Feb 20185:57 pmRNSHolding(s) in Company
1st Feb 201812:26 pmRNSTotal Voting Rights
22nd Jan 20187:00 amRNSAbcam Signs Exclusive License Agreement with Roche
18th Jan 201812:02 pmRNSHolding(s) in Company
8th Jan 201812:00 pmRNSAbcam present at J.P. Morgan Healthcare Conference
5th Jan 20187:00 amRNSHalf Year Trading Update
3rd Jan 20189:10 amRNSTotal Voting Rights
12th Dec 201710:37 amRNSDirector/PDMR Shareholding
1st Dec 20173:07 pmRNSTotal Voting Rights
15th Nov 20177:00 amRNSResult of AGM and Directorate Change
14th Nov 20177:00 amRNSAGM Statement
6th Nov 20174:48 pmRNSDirector/PDMR Shareholding
6th Nov 20174:42 pmRNSDirector/PDMR Shareholding
6th Nov 20174:40 pmRNSDirector/PDMR Shareholding
1st Nov 20174:46 pmRNSTotal Voting Rights
30th Oct 20179:55 amRNSDirector/PDMR Shareholding
17th Oct 20173:06 pmRNSHolding(s) in Company
11th Oct 20177:00 amRNSDirectorate Change
3rd Oct 201711:16 amRNSTotal Voting Rights
22nd Sep 20173:32 pmRNSAnnual Financial Report
22nd Sep 20177:00 amRNSDirector/PDMR Shareholding
18th Sep 20174:36 pmRNSDirector/PDMR Shareholding
11th Sep 20177:00 amRNSPreliminary Results
1st Sep 20179:41 amRNSTotal Voting Rights
25th Aug 201711:00 amRNSHolding(s) in Company
17th Aug 201710:00 amRNSHolding(s) in Company
9th Aug 20173:18 pmRNSBlock listing Interim Review
1st Aug 20179:45 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSPre-Close Period Update
3rd Jul 20179:54 amRNSTotal Voting Rights
7th Jun 20174:23 pmRNSDirector/PDMR Shareholding
1st Jun 20172:41 pmRNSTotal Voting Rights
18th May 20173:17 pmRNSApplication for admission to trading
18th May 20177:00 amRNSFinal Performance-Based AxioMx Milestone Payment
3rd May 201711:25 amRNSDirector/PDMR Shareholding
2nd May 201710:27 amRNSTotal Voting Rights
18th Apr 20172:24 pmRNSDirector/PDMR Shareholding
10th Apr 20173:37 pmRNSDirector/PDMR Shareholding
3rd Apr 20171:53 pmRNSTotal Voting Rights
23rd Mar 20177:00 amRNSDirector/PDMR Shareholding
21st Mar 20177:00 amRNSDirector/PDMR Shareholding
6th Mar 20177:00 amRNSInterim Results
1st Mar 20174:05 pmRNSTotal Voting Rights
9th Feb 20178:52 amRNSBlock listing Interim Review
1st Feb 201712:09 pmRNSTotal Voting Rights
10th Jan 20177:00 amRNSHalf Year Trading Update
3rd Jan 20174:34 pmRNSTotal Voting Rights
15th Dec 201611:19 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.